Frankfurt Rhine-Main Metropolitan Area
Expert in solid oral dosage forms with special interest in coating, extrusion/spheronisation, hot melt extrusion, multiparticulates, sustained release dosage forms and solubilisation of poorly soluble compounds; Focus on Quality by Design to enable systematic drug development from the start; Experience in managing of international teams, both as project team leader and line manager, for multiple projects from preclinical to launch; Extensive formulation and strategic experience in the development of solid dosage forms from preclinical development to launch for propriatary drug compounds and branded generics. International Executive MBA at SGBS St. Gallen and Alpen - Adria University Klagenfurt. Strong interest in QbD as a competitive advantage to improve profitability in the pharmaceutical industry. Specialties: Invited speaker at national and international seminars on sustained release formulations, pelletisation, coating, wet extrusion, hot melt extrusion, highly potent drug products and Quality by Design driven development; Member and deputy head of the APV's focus group "Solid Dosage Forms"
International role responsible for all Corden sites for the introduction of new technologies in pharmaceutical manufacturing and the global roll out of Quality by Design
Head of development and production at Corden Pharma Plankstadt Member of the executice board of Corden Pharma Plankstadt with overall responsibility for development (including formulation development, clinical trial supplies and project managment) and commercial production (bulk manufacturing and drug product packaging) at Corden Pharma in Plankstadt
Executive responsibility for all development and bulk production at the Plankstadt site. Executive responsibility for the Business Development at the Plankstadt site.
Director Pharmaceutical Development, Konstanz heading the section of Pharmaceutical Development, Konstanz at Nycomed GmbH in Konstanz. This section includes the departments of clinical trial supplies, pharmaceutical quality, pharmaceutical CMC management, pharmaceutical formulation and biopharmaceuticals, each of which is headed by a senior group leader and an associate director; Disciplinary responsibility for 43 people directing all pharmaceutical development business at the site in Konstanz and reporting to the head of Technical Development. Jan. - May 2008 Associate Director Pharmaceutical Development, Konstanz heading the section of pharmaceutical development at Nycomed GmbH in Konstanz; Disciplinary responsibility for a total of 35 employees in 5 departments/groups
Jan. 2006 – Dec. 2007 Group leader “Technical Development of New Therapeutic Entities” at Grünenthal GmbH responsible for three teams of scientists and senior scientists; Lead and co-ordination of all development work in these teams; 16 direct reports; Jan. 2003 – Dec. 2007 Core team member in the development team for Grünenthal’s SIP® technology; Nov. 2002 - Dec. 2005 Team leader in the department of pharmaceutical development (SIP® technology - an innovative dosage form for the treatment of antibiotic infections in children) at Grünenthal GmbH in Aachen July 2000 – Oct. 2002 International project manager for NCEs from GLP to “first in man” and the start of a phase IIa at Grünenthal GmbH, Aachen End 2000 –Oct. 2002 Team leader in the department of Pharmaceutical Development (oral drug delivery systems, sustained release products) at Grünenthal GmbH in Aachen May 1997- End 2000 Team leader in the department of Pharmaceutical Development (oral, solid dosage forms) at Grünenthal GmbH in Aachen
Post-doctoral studies at SmithKline Beecham Pharmaceuticals in Great Burgh, Great Britain to widen my experience in the subject of sustained release formulations for oral dosage forms with a focus on drugs with poor water solubility and their solubilisation